MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting
HCC prognosis
HCC therapy
S-adenosylmethionine
methionine metabolism
methyladenosyltransferases
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
19 Apr 2019
19 Apr 2019
Historique:
received:
08
11
2018
accepted:
04
03
2019
entrez:
11
5
2019
pubmed:
11
5
2019
medline:
11
5
2019
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is characterized by the down-regulation of the liver-specific methyladenosyltransferase 1A (
Identifiants
pubmed: 31073374
doi: 10.18632/oncotarget.26838
pii: 26838
pmc: PMC6497462
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2835-2854Subventions
Organisme : NIAAA NIH HHS
ID : F32 AA020150
Pays : United States
Organisme : NIAAA NIH HHS
ID : K01 AA022372
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST The authors declare no conflicts of interest.
Références
FASEB J. 2000 Jan;14(1):95-102
pubmed: 10627284
Crit Rev Oncog. 2000;11(1):19-62
pubmed: 10795626
Gastroenterology. 2003 Apr;124(4):940-8
pubmed: 12671891
J Clin Pathol. 1992 May;45(5):416-9
pubmed: 1350788
J Biol Chem. 2003 Dec 19;278(51):50887-96
pubmed: 14530285
Cancer Res. 1992 Sep 15;52(18):4979-86
pubmed: 1516054
Biochim Biophys Acta. 2006 Apr;1765(2):126-47
pubmed: 16216419
Cancer Res. 1975 Nov;35(11 Pt 1):3214-23
pubmed: 171067
Gastroenterology. 2007 Jul;133(1):207-18
pubmed: 17631143
Int J Cancer. 2007 Dec 1;121(11):2410-20
pubmed: 17680562
Cell Death Differ. 2008 Jul;15(7):1187-95
pubmed: 18483491
World J Gastroenterol. 2008 Aug 7;14(29):4633-42
pubmed: 18698677
Am J Pathol. 1977 Sep;88(3):595-618
pubmed: 18937
Oncogene. 2008 Oct 27;27(50):6473-88
pubmed: 18955974
Cell Res. 2009 Mar;19(3):358-69
pubmed: 19048023
Hepatology. 2009 Aug;50(2):462-71
pubmed: 19444874
Gastroenterology. 2010 May;138(5):1943-53
pubmed: 20102719
Am J Clin Pathol. 2011 Oct;136(4):594-603
pubmed: 21917682
Hepatology. 2012 Jul;56(1):165-75
pubmed: 22318685
Cell Biochem Funct. 2013 Jan;31(1):82-5
pubmed: 22886454
J Clin Invest. 2013 Jan;123(1):285-98
pubmed: 23241961
Front Biosci (Landmark Ed). 2013 Jan 01;18:199-223
pubmed: 23276918
Exp Cell Res. 2013 Jul 15;319(12):1902-11
pubmed: 23588207
J Hepatol. 2013 Oct;59(4):830-41
pubmed: 23665184
J Biol Chem. 2013 Aug 9;288(32):23161-70
pubmed: 23814050
PLoS One. 2013 Sep 30;8(9):e75628
pubmed: 24098708
PLoS One. 2013 Nov 14;8(11):e80053
pubmed: 24244607
Carcinogenesis. 1989 Jul;10(7):1183-92
pubmed: 2472229
Drug Discov Ther. 2014 Jun;8(3):102-9
pubmed: 25031041
IUCrJ. 2014 Jun 12;1(Pt 4):240-9
pubmed: 25075345
PLoS One. 2014 Aug 20;9(8):e105570
pubmed: 25140799
Biomed Pharmacother. 2014 Oct;68(8):911-6
pubmed: 25458789
Cell Cycle. 2014;13(17):2733-43
pubmed: 25486360
PLoS One. 2015 Jan 26;10(1):e0116170
pubmed: 25621839
Cancer Res. 2015 Apr 1;75(7):1433-44
pubmed: 25634212
J Exp Clin Cancer Res. 2015 Jan 31;34:8
pubmed: 25636908
Cancer Res. 1989 Apr 1;49(7):1850-6
pubmed: 2564313
Am J Pathol. 2015 Apr;185(4):1135-44
pubmed: 25794709
Cancer Cell Int. 2015 Jun 18;15:62
pubmed: 26109910
Anticancer Agents Med Chem. 2016;16(4):414-23
pubmed: 26179263
Drug Des Devel Ther. 2015 Jul 16;9:3607-16
pubmed: 26213461
World J Gastroenterol. 2015 Dec 21;21(47):13268-76
pubmed: 26715809
J Mol Med (Berl). 2016 Dec;94(12):1313-1326
pubmed: 27695879
Science. 2016 Sep 30;353(6307):1549-1552
pubmed: 27708105
Sci Rep. 2016 Dec 05;6:38311
pubmed: 27917899
Adv Clin Exp Med. 2016 Sep-Oct;25(5):971-975
pubmed: 28028963
Cancer Sci. 2017 Mar;108(3):338-346
pubmed: 28100026
Sci Rep. 2017 Feb 20;7:42680
pubmed: 28218277
Mol Med Rep. 2017 May;15(5):2720-2726
pubmed: 28447723
Mol Cell Biochem. 2018 Apr;441(1-2):89-98
pubmed: 28887744
Exp Biol Med (Maywood). 2018 Jan;243(2):107-117
pubmed: 29141455
Biomed Pharmacother. 2017 Dec;96:884-891
pubmed: 29145165
Ann Gastroenterol. 2018 Sep-Oct;31(5):552-560
pubmed: 30174391
Hepatology. 1995 Sep;22(3):983-93
pubmed: 7657307